🇺🇸 GW642444 in United States

25 US adverse-event reports

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

• Window: 22 April 2025 – 22 April 2026
• Total reports: 25

Most-reported reactions

1. Chronic Obstructive Pulmonary Disease — 11 reports (44%)
2. Pneumonia — 4 reports (16%)
3. Dysphonia — 2 reports (8%)
4. Oesophageal Candidiasis — 2 reports (8%)
5. Amnesia — 1 report (4%)
6. Anaphylactoid Reaction — 1 report (4%)
7. Angina Unstable — 1 report (4%)
8. Aortic Aneurysm — 1 report (4%)
9. Asthma — 1 report (4%)
10. Atrial Fibrillation — 1 report (4%)

Source database →

Frequently asked questions

Is GW642444 approved in United States?

GW642444 does not currently have US marketing authorisation in our dataset.

Who is the marketing authorisation holder for GW642444 in United States?

GlaxoSmithKline is the originator. The local marketing authorisation holder may differ — check the official source linked above.